Journal of Shandong University (Health Sciences) ›› 2020, Vol. 58 ›› Issue (6): 1-7.doi: 10.6040/j.issn.1671-7554.0.2020.048
GENG Hongzhi, LI Wei, YAN Chuanzhu, LYU Xiaoqing, LIN Pengfei
CLC Number:
[1] Spiro AJ, Shy GM, Gonatas NK, et al. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy[J]. Arch Neurol, 1966, 14(1):1-14. [2] Zhao Y, Zhao Z, Hu J, et al. Characterization and genetic diagnosis of centronuclear myopathies in seven Chinese patients[J]. Neurol Sci, 2018, 39(12): 2043-2051. [3] Lin P, Liu X, Yan C. DNM2 mutations in Chinese Han patients with centronuclear myopathy[J]. Neurol Sci, 2016, 37(6): 995-998. [4] Annoussamy M, Lilien C, Gidaro T, et al. X-linked myotubular myopathy: A prospective international natural history study[J]. Neurology, 2019, 92(16): e1852-e1867. doi: 10.1212/WNL.0000000000007319. [5] Oliveira J, Oliveira ME, Kress W, et al. Expanding the MTM1 mutational spectrum: novel variants including the first multi-exonic duplication and development of a locus-specific database[J]. Eur J Hum Genet, 2013, 21(5): 540-549. [6] Tosch V, Vasli N, Kretz C, et al. Novel molecular diagnostic approaches for X-linked centronuclear(myotubular)myopathy reveal intronic mutations[J]. Neuromuscul Disord, 2010, 20(6): 375-381. [7] Smith BK, Goddard M, Childers MK. Respiratory assessment in centronuclear myopathies[J]. Muscle Nerve, 2014, 50(3): 315-326. [8] Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear(myotubular)myopathy[J]. Orphanet J Rare Dis, 2008, 3: 26. doi:10.1186/1750-1172-3-26. [9] Jungbluth H, Gautel M. Pathogenic mechanisms in centronuclear myopathies[J]. Front Aging Neurosci, 2014, 6: 339.doi: 10.3389/fnagi.2014.00339. eCollection 2014. [10] Tinelli E, Pereira J, Suter U. Muscle-specific function of the centronuclear myopathy and Charcot-Marie-Tooth neuropathy-associated dynamin 2 is required for proper lipid metabolism, mitochondria, muscle fibers, neuromuscular junctions and peripheral nerves[J]. Hum Mol Genet, 2013, 22(21): 4417-4429. [11] Zhao M, Maani N, Dowling JJ. Dynamin 2(DNM2)as cause of, and modifier for, human neuromuscular disease[J]. Neurotherapeutics, 2018, 15(4): 966-975. [12] Bevilacqua J, Bitoun M, Biancalana V, et al. “Necklace” fibers, a new histological marker of late-onset MTM1-related centronuclear myopathy[J]. Acta Neuropathol, 2009, 117(3): 283-291. [13] 刘新红, 吴化民, 杨申, 等. 动力蛋白-2相关中央核肌病临床诊断学特点及文献回顾[J]. 中华临床医师杂志(电子版), 2015, 9(13): 2477-2481. LIU Xinhong, WU Huamin, YANG Shen, et al. The clinical diagnosis characteristics of DNM2-related centronuclear myopathy and literature review[J]. Chinese Journal of Clinicians(Electronic Edition), 2015, 9(13): 2477-2481. [14] Funayama K, Shimizu H, Tanaka H, et al. An autopsy case of peliosis hepatis with X-linked myotubular myopathy[J]. Leg Med(Tokyo), 2019, 38: 77-82.doi: 10.1016/j.legalmed.2019.04.005. [15] 黄玲莉, 李汶, 卢光琇, 等. 中央核肌病患者的孕产风险评估及遗传咨询[J]. 中国现代医学杂志, 2012, 22(36): 40-44. HUANG Lingli, LI Wen, LU Guangxiu, et al. Risk analysis of pregnancy and delivery in females with centronuclear myopathy and genetic counseling[J]. China Journal of Modern Medicine, 2012, 22(36): 40-44. [16] 王朝霞, 袁云, 姜玉武, 等. 3例中央核肌病的临床和病理特点[J]. 中风与神经疾病杂志, 2003,20(2): 44-46. WANG Zhaoxia, YUAN Yun, JIANG Yuwu, et al. Clinical and myopathological feature in 3 cases with centronuclear myopathy[J]. Journal of Apoplexy and Nervous Diseases, 2003, 20(2): 44-46. [17] Chen T, Pu C, Wang Q, et al. Clinical, pathological, and genetic features of dynamin-2-related centronuclear myopathy in China[J]. Neurol Sci, 2015, 36(5): 735-741. [18] 张永庆, 顾卫红, 郝莹, 等. 常染色体显性遗传中央核肌病一家系临床、病理和分子生物学特点[J]. 中华神经科杂志, 2007, 40(10): 663-666. ZHANG Yongqing, GU Weihong, HAO Ying, et al. Clinical, pathological and molecular biological study on a family of autosomal dominant inherited centronuclear myopathy[J]. Chinese Journal of Neurology, 2007, 40(10): 663-666. [19] Romero N. Centronuclear myopathies: a widening concept[J]. Neuromuscul Disord, 2010, 20(4): 223-238. [20] Herman GE, Finegold M, Zhao W, et al. Medical complications in long-term survivors with X-linked myotubular myopathy[J]. J Pediatr, 1999, 134(2): 206-214. [21] Tsai TC, Horinouchi H, Noguchi S,et al. Characterization of MTM1 mutations in 31 Japanese families with myotubular myopathy, including a patient carrying 240 kb deletion in Xq28 without male hypogenitalism[J]. Neuromuscul Disord, 2005, 15(3): 245-252. [22] 毕学杰, 薛春梅, 薛平, 等. 晚发型肌管肌病1例[J]. 临床与实验病理学杂志, 2006,22(4): 510-511. BI Xuejie, XUE Chunmei, XUE Ping, et al. One case of late onset myotubular myopathy[J]. Chinese Journal of Clinical and Experimental Pathology, 2006, 22(4): 510-511. [23] Nishikawa A, Iida A, Hayashi S, et al. Three novel MTM1 pathogenic variants identified in Japanese patients with X-linked myotubular myopathy[J]. Mol Genet Genomic Med, 2019, 7(5): e621.doi: 10.1002/mgg3.621. [24] Laporte J, Blondeau F, Buj-Bello A, et al. The myotubularin family: from genetic disease to phosphoinositide metabolism[J]. Trends Genet, 2001, 17(4): 221-228. [25] Robinson FL, Dixon JE. Myotubularin phosphatases: policing 3-phosphoinositides[J]. Trends Cell Biol, 2006, 16(8): 403-412. [26] Meijer AJ, Klionsky DJ. Vps34 is a phosphatidylinositol 3-kinase, not a phosphoinositide 3-kinase[J]. Autophagy, 2011, 7(6): 563-564. |
[1] | SUN Li-feng1, JU Yun-fei2, JIANG Li-ping3, WANG Jin-rong1, FENG Yi-zhen1. Review of nine cases of Xlinked agammaglobulinemia [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(9): 120-123. |
|